This content is machine translated Advanced breast cancer Next-generation SERD therapy with promising results The results of the Phase III EMBER-3 trial of imlunestrant, a next-generation oral selective oestrogen receptor degrader (SERD) for patients with hormone receptor-positive breast cancer in ER-positive, HER2-negative advanced breast...…
